scholarly journals Ascending Aortic Calcification as a Potential Predictor for Low Bone Mineral Density: A Pilot Study

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Hirofumi Bekki ◽  
Takeshi Arizono ◽  
Yuki Suzuki ◽  
Akihiko Inokuchi ◽  
Takahiro Hamada ◽  
...  

Background. Identifying the factors related to low bone mineral density (BMD) can have significant implications for preventing hip fractures. The correlation between ascending aortic calcification and BMD has never been reported. Therefore, the purpose of the current study is to confirm the hypothesis that ascending aortic calcification can be used as a predictive factor for low BMD and to find a radiographic sign to show it. Method. Plain film and computed tomography (CT) images of the thorax were obtained from 91 patients with hip fractures. Using the images, the calcification line of the ascending aorta adjacent to the aortic arch was evaluated. A prominent calcification line confirmed by both plain film and CT was classified as +2. A line which was ambiguous on plain film but confirmed by CT was classified as +1. Cases with no calcification were categorized as 0 (control). We compared the classified score with the BMD and calculated the kappa coefficient to measure intraobserver reliabilities for this radiographic finding. Results. Twenty-eight patients showed a +2 line, twenty-four patients showed a +1 line, and thirty-nine patients showed 0 lines. The median BMD of each group was 0.37 for the +2 line, 0.45 for the +1 line, and 0.51 for the 0 line. The BMD for the +2 group was significantly lower than the others. The kappa coefficient was approximately 0.6 ( p < 0.01 ). Conclusion. The imaging finding of calcification of the ascending aorta might be considered as a potential surrogate marker of low BMD. In such subjects, BMD might be ordered for the confirmation of diagnosis of osteoporosis. Mini-Abstract. The Aortic Arch Tail Sign, a calcification line on the ascending aorta, was relevant to low BMD in the current study. BMD can be ordered for the confirmation of diagnosis of osteoporosis in a subject incidentally found to have ascending aorta calcification on X-ray or CT.

2012 ◽  
Vol 25 (3) ◽  
pp. 310-318 ◽  
Author(s):  
Kira B. Harris ◽  
Kimberly L. Nealy ◽  
Delilah J. Jackson ◽  
Phillip L. Thornton

Osteoporosis is a leading cause of debility and declining quality of life in postmenopausal women worldwide. Treatment of osteoporosis has been ubiquitous throughout the developed world since the mid-1990s, most notably with the introduction of bisphosphonates in 1995. Nonetheless, the incidence of hip fractures increased by 25% between 1990 and 2000, despite advances in osteoporosis therapy. Studies indicate that bone density increases over the first 3 years of bisphosphonate therapy and then plateaus or perhaps even declines, placing these patients at greater risk of fracture. Since hip fractures are associated with increased morbidity, mortality, and increased cost of health care, improvements in treating osteoporosis are critical. Denosumab is a novel monoclonal antibody targeted against the receptor activator of nuclear factor-κB ligand (RANKL) that inhibits osteoclast activity. Initial data suggest that denosumab increases bone mineral density for greater than 3 years. Of greater importance, denosumab has been shown to decrease vertebral fractures by 68%, nonvertebral fractures by 19%, and hip fractures by 42% for at least 36 months. Data also indicate that the safety profile of denosumab is equivalent to other drugs used in osteoporosis management, but potential risks of immunosuppression and cancer have been hypothesized.


2019 ◽  
Vol 112 (11) ◽  
pp. 472-475 ◽  
Author(s):  
Manuel Sosa Henríquez ◽  
María Jesús Gómez de Tejada Romero ◽  
María Escudero-Socorro ◽  
Oscar Torregrosa Suau

Summary A significant loss of bone mineral density and the appearance of multiple vertebral fractures after discontinuation of denosumab treatment have been described. To date, no hip fractures have been reported. We present three cases of patients who suffered femoral fractures after denosumab suppression.


Bone ◽  
2010 ◽  
Vol 46 (2) ◽  
pp. 330-335 ◽  
Author(s):  
Jyrki A. Kettunen ◽  
Olli Impivaara ◽  
Urho M. Kujala ◽  
Miika Linna ◽  
Juhani Mäki ◽  
...  

1995 ◽  
Vol 9 (6) ◽  
pp. 470-475 ◽  
Author(s):  
Douglas R. Dirschl ◽  
Richard C. Henderson ◽  
Ward S. Oakley

2015 ◽  
Vol 48 (6) ◽  
pp. 1043-1051 ◽  
Author(s):  
Xuanliang Neil Dong ◽  
Rajeshwar Pinninti ◽  
Timothy Lowe ◽  
Patricia Cussen ◽  
Joyce E. Ballard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document